Sionna Therapeutics Net Income From Continuing Ops Over Time
| SION Stock | 36.11 0.86 2.44% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Sionna Therapeutics Performance and Sionna Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Sionna diversify its offerings? Factors like these will boost the valuation of Sionna Therapeutics. If investors know Sionna will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sionna Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Sionna Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sionna Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Sionna Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sionna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sionna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sionna Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Sionna Therapeutics and related stocks such as Janux Therapeutics, Abcellera Biologics, and Maze Therapeutics Common Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JANX | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (6.8 M) | (32.7 M) | (63.1 M) | (62.6 M) | (69 M) | (62.1 M) | (65.2 M) |
| ABCL | 308.9 K | 308.9 K | 308.9 K | 308.9 K | 308.9 K | 308.9 K | 308.9 K | 308.9 K | 308.9 K | (2.2 M) | 118.9 M | 153.5 M | 158.5 M | (146.4 M) | (162.9 M) | (146.6 M) | (139.2 M) |
| MAZE | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (100.4 M) | 52.2 M | 60.1 M | 63.1 M |
| BHVN | (118.7 M) | (118.7 M) | (118.7 M) | (118.7 M) | (118.7 M) | (118.7 M) | (118.7 M) | (118.7 M) | (118.7 M) | (118.7 M) | (118.7 M) | (848.4 M) | (570.3 M) | (408.2 M) | (846.4 M) | (761.8 M) | (799.9 M) |
| CLDX | (44.8 M) | (44.8 M) | (59.1 M) | (81.5 M) | (118.1 M) | (127.2 M) | (128.5 M) | (93 M) | (151.2 M) | (50.9 M) | (59.8 M) | (70.5 M) | (112.3 M) | (124.6 M) | (157.9 M) | (142.1 M) | (149.2 M) |
| VERA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (53.4 M) | (32.6 M) | 89.1 M | (102.8 M) | (152.1 M) | (136.9 M) | (130.1 M) |
| XERS | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (26.6 M) | (60.1 M) | (125.6 M) | (91.1 M) | (122.7 M) | (94.7 M) | (62.3 M) | (54.8 M) | (49.4 M) | (51.8 M) |
| ZYME | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (19.2 M) | (33.8 M) | (10.4 M) | (36.6 M) | (145.4 M) | (180.6 M) | (211.8 M) | 124.3 M | (118.7 M) | (122.7 M) | (110.4 M) | (115.9 M) |
| ARDX | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (29.6 M) | (112.4 M) | (64.3 M) | (91.3 M) | (94.9 M) | (94.3 M) | (158.2 M) | (67.2 M) | (66.1 M) | (39.1 M) | (35.2 M) | (37 M) |
| IMNM | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (10.4 M) | (17.8 M) | (24.7 M) | (36.9 M) | (106.8 M) | (293 M) | (263.7 M) | (250.5 M) |
Sionna Therapeutics and related stocks such as Janux Therapeutics, Abcellera Biologics, and Maze Therapeutics Common Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Sionna Therapeutics Common | SION |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 21 Hickory Drive, |
| Exchange | NASDAQ Exchange |
null 36.11
Check out Sionna Therapeutics Performance and Sionna Therapeutics Correlation. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Sionna Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.